Page 2,369«..1020..2,3682,3692,3702,371..2,3802,390..»

California Stem Cell Agency to Court Patient Groups This Summer

Posted: May 23, 2013 at 12:28 pm

Jonathan Thomas, chairman of the California stem cell agency, said this morning that he and a team from the agency will begin a round of meetings this summer with patient advocate groups throughout the state.

He said the effort is aimed at keeping the groups up to speed on developments at CIRM. While Thomas did not mention it to the agency's governing board, it is also critical that the agency have strong support from patient advocate groups as it tries to develop new sources of funding, either public or private.

The agency will run out of cash for new grants in 2017 and hopes to have a plan for the future before the board later this year. Its initial assumptions include as much as $200 million in onetime public funding with more cash coming from the private sector.

Currently the agency is funded by state bonds at a cost of about $6 billion, including interest. It spends roughly $300 million a year on grants and loans for research.Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/lra474LHezU/california-stem-cell-agency-to-court.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on California Stem Cell Agency to Court Patient Groups This Summer

BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress

Posted: May 23, 2013 at 9:44 am

BOTHELL, Wash., May 23, 2013 /PRNewswire/ --BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced its participation at the Terrapinn World Stem Cells & Regenerative Medicine Congress 2013 this week in London.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Dr. Aby J. Mathew, BioLife's Senior Vice President and Chief Technology Officer, will make a presentation titled "Critical Stability and Biopreservation Considerations for Manufacturing, Storage and Clinical Delivery of Cell and Tissue Products," to the audience of executives and product development managers of commercial regenerative medicine companies. The presentation outlines the risk to clinical and commercial success of cell and tissue products due to stability limitations from the use of non-optimized storage, transport and cryopreservation freeze media. Comparative data illustrating the superior preservation efficacy of BioLife's HypoThermosol storage and shipping media, and CryoStor cryopreservation freeze media will be presented on relevant cell and tissue types.

Mike Rice, Chief Executive Officer, commented, "We continue to build traction in the high growth regenerative medicine market, and estimate that more than 65 percent of the presenting companies at this conference have adopted our best in class, clinical grade biopreservation media products. A key value-added service we provide, which directly translates into expanded product adoption, is the high quality consulting our team offers to prospective and current customers. Biopreservation outcomes such as cell and tissue shelf life, viability and recovery can greatly impact commercial potential. The combination of the efficacy and quality of our proprietary platform technology, along with our expert technical consulting services, is now recognized and highly valued in the development and commercialization of regenerative medicine products and therapies."

The regenerative medicine market is expected to grow to more than $35 billion by 2019, according to TriMark Publications' recently published "Regenerative MedicineMarkets" report. BioLife's addressable portion of the market is the demand for reagents used to store, ship and freeze source material and manufactured doses of cell-based products and therapies.

For a list of upcoming events, please visit http://biolifesolutions.com/cell-therapy/category/events/.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company's proprietary HypoThermosol and CryoStor platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce biopreservation-induced cell damage and death. BioLife's enabling technology provides academic and clinical researchers, and commercial companies significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit http://www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

More here:
BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress

Posted in Regenerative Medicine | Comments Off on BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress

Italy approves law on controversial stem cell therapy

Posted: May 23, 2013 at 9:43 am

Italian lawmakers on Wednesday gave their final approval to a law that allows limited use of a controversial type of stem cell therapy which has been condemned by many scientists but has given hope to families of terminally-ill children.

The law gives the go-ahead for therapy being carried out by the Stamina Foundation on dozens of patients to continue, and allows for an 18-month period of clinical trials for the procedure, which had previously been blocked by Italian authorities.

The bill was amended from an earlier version and states the therapy must be carried out under regulatory oversight and using cells made according to the Good Manufacturing Practice (GMP) which the Stamina Foundation has not adhered to.

The Stamina Foundation says its treatment is based on mesenchymal stem cells and could treat diseases like spinal cord injury and motor neurone disease.

But leading scientists have warned that there is no evidence to suggest the treatment could work and no way to know that it will not cause harm.

Umberto Galderisi from the University of Naples and president of Stem Cell Italy, is among critics of the bill.

He said the clinical trials would "never have been allowed" if scientific accepted practice had been followed.

"This is legislating on the basis of public opinion. It means exploiting suffering. Patients are not lab rats," he told AFP, adding there were "no scientific certainties" the therapy could work.

"We do not want Italy to become one of those countries like China or Ukraine where there are untested scientific trials," he said.

Patients lobbied for the therapy to be given the go-ahead, receiving support from various celebrities including actress Gina Lollobrigida.

Go here to read the rest:
Italy approves law on controversial stem cell therapy

Posted in Cell Therapy | Comments Off on Italy approves law on controversial stem cell therapy

Stem Cell Therapy Worldwide – Video

Posted: May 23, 2013 at 9:42 am


Stem Cell Therapy Worldwide
http://www.placidway.com/ - Looking for best and affordable stem cell therapy? Placidway offers best and most affordable stem cell therapy with the top docto...

By: placidways #39;s channel

Go here to see the original:
Stem Cell Therapy Worldwide - Video

Posted in Stem Cell Therapy | Comments Off on Stem Cell Therapy Worldwide – Video

LaViv stem cell therapy for acne scars – Video

Posted: May 23, 2013 at 9:42 am


LaViv stem cell therapy for acne scars
Dermatologist and cosmetic surgeon Dr. Melanie Palm of http://www.artofskinmd.com discusses and demonstrates the use of LaVIV, the first available personalized stem...

By: melaniepalm

See more here:
LaViv stem cell therapy for acne scars - Video

Posted in Stem Cell Therapy | Comments Off on LaViv stem cell therapy for acne scars – Video

Nature Reports on Lee Hood Conflict Case

Posted: May 22, 2013 at 4:18 pm

The journal Nature and genomeweb.com
today picked up the story from the California Stem Cell Report about
the conflict of interest case at the California stem cell agency involving renown scientist Lee Hood of
Seattle, Wash.

Science news aggregators on the
Internet also relayed various versions of the story. The facts were
first reported on this blog yesterday. The matter involved a $24
million application for a genome project involving Irv Weissman of
Stanford. Hood was one of the reviewers in the round. Hood and
Weissman are longtime friends and own property together in Montana.
They have also have a number of professional relationships.
In piece by Ewen Callaway, Nature
additionally referred to ongoing conflict of interest issues at the agency,
including the findings of an Institute of Medicine study. Harold Shapiro, head of the study, said the agency directors make "proposals to themselves, essentially, regarding what should be funded. They cannot exert independent oversight." 
The genomeweb item was also brief and
did not mention the IOM study.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/xBpF71FS1Ys/nature-reports-on-lee-hood-conflict-case.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Nature Reports on Lee Hood Conflict Case

Italy approves controversial stem cell therapy

Posted: May 22, 2013 at 2:42 pm

Italian lawmakers on Wednesday gave their final approval to a law that allows limited use of a controversial type of stem cell therapy which has been condemned by many scientists but has given hope to families of terminally-ill children.

The law gives the go-ahead for therapy being carried out by the Stamina Foundation on dozens of patients to continue, and allows for an 18-month period of clinical trials for the procedure, which had previously been blocked by Italian authorities.

The bill was amended from an earlier version and states the therapy must be carried out under regulatory oversight and using cells made according to the Good Manufacturing Practice (GMP) which the Stamina Foundation has not adhered to.

The Stamina Foundation says its treatment is based on mesenchymal stem cells and could treat diseases like spinal cord injury and motor neurone disease.

But leading scientists have warned that there is no evidence to suggest the treatment could work and no way to know that it will not cause harm.

Patients lobbied for the therapy to be given the go-ahead, receiving support from various celebrities including actress Gina Lollobrigida.

At one demonstration, protesters wore T-shirts with the slogan: "Yes to Stamina, Yes to Life".

The association Stem Cell Research Italy has branded the new law as "unacceptable" saying the therapy was not backed up by clinical data published in peer-reviewed academic journals.

US journal Nature said it was a "rogue" therapy.

Follow this link:
Italy approves controversial stem cell therapy

Posted in Cell Therapy | Comments Off on Italy approves controversial stem cell therapy

Google CEO s Condition Spotlights Vocal Cord Paralysis and Its Treatment

Posted: May 22, 2013 at 8:30 am

When Google CEO Larry Page blogged about his struggles speaking and, at times, breathing last week on his Google+ page he spotlighted a rare condition, bilateral vocal cord paralysis , which leaves sufferers short of breath and with few viable treatment options. This is likely to change in coming years. Page has deep pockets and has promised to fund research into the disorder via the Voice Health Institute . In the meantime scientists are experimenting with electrical stimulation technologies to enhance existing voice therapy as well as surgical treatments. [More]



Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article



Source:
http://rss.sciam.com/click.phdo?i=b3c657c36bd85f3126649923bb8701fe

Posted in Gene therapy | Comments Off on Google CEO s Condition Spotlights Vocal Cord Paralysis and Its Treatment

Embryonic Stem Cells Generate Immune System – Video

Posted: May 22, 2013 at 3:42 am


Embryonic Stem Cells Generate Immune System
Researchers at UC San Francisco have developed thymus tissue from human embryonic cells and used it to generate an immune system in mice. The achievement has...

By: UCSFPublicAffairs

Go here to see the original:
Embryonic Stem Cells Generate Immune System - Video

Posted in Stem Cell Videos | Comments Off on Embryonic Stem Cells Generate Immune System – Video

Are blood stem cells effective? – Video

Posted: May 22, 2013 at 3:42 am


Are blood stem cells effective?
http://www.stemcellsarthritistreatment.com Which stem cells are most effective for treating osteoarthritis? A study published in the journal Arthroscopy by Saw and colleagues has drawn some...

By: Nathan Wei

View original post here:
Are blood stem cells effective? - Video

Posted in Stem Cell Videos | Comments Off on Are blood stem cells effective? – Video

Page 2,369«..1020..2,3682,3692,3702,371..2,3802,390..»